arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Solid Biosciences Inc.

SLDB
$6.16 ▼ -0.36 (-5.52%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
39 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Solid Biosciences Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $885.1M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -12.1% →
FCF / Share $-0.37 ↗
Trailing P/E —
Price / Book 1.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-56.74M
↓ -44.4% —
FCF / Share Free cash flow per share
$-0.37
↑ +8.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
9
Cash Quality ↓
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 39 quarters